Anti-Phospholamban (phospho S16) antibody [EPR1911] (ab92697)

Overview

• Product nameAnti-Phospholamban (phospho S16) antibody [EPR1911]See all Phospholamban primary antibodies ...
• Description
  Rabbit monoclonal [EPR1911] to Phospholamban (phospho S16)
• Tested applicationsWB, IP more details
• Species reactivity
  Reacts with: Mouse, Human
  

  Does not react with

  Rat
• Immunogen

  A phospho specific peptide corresponding to residues surrounding Serine 16 of Human Phospholamban.

• Positive controlFetal heart lysate
• General notesProduced under U.S. Patent No. 5,675,063.

Properties

• FormLiquid
• Storage instructionsStore at -20°C. Stable for 12 months at -20°C
• Storage bufferPBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
• PurityTissue culture supernatant
• Purification notesThis antibody is not purified. It is provided in cell supernatant and storage buffer.
• Clonality Monoclonal
• Clone numberEPR1911
• IsotypeIgG
• Research Areas
  • Metabolism
  • Types of disease
  • Cancer

  • Signal Transduction
  • Metabolism
  • Plasma Membrane
  • ATPases

  • Signal Transduction
  • Metabolism
  • Plasma Membrane
  • Channels

  • Signal Transduction
  • Signaling Pathway
  • Calcium Signaling
  • Other

  • Signal Transduction
  • Signaling Pathway
  • Calcium Signaling
  • Calcium Channels

  • Cardiovascular
  • Vasculature
  • Vasodilation
  • Other

  • Cardiovascular
  • Heart
  • Contractility
  • Inotropics

  • Tags & Cell Markers
  • Cell Type Markers
  • Other Cell Types

Applications

Target

• FunctionPhospholamban has been postulated to regulate the activity of the calcium pump of cardiac sarcoplasmic reticulum.
• Tissue specificityHeart.
• Involvement in diseaseDefects in PLN are the cause of cardiomyopathy dilated type 1P (CMD1P) [MIM:609909]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
  Defects in PLN are the cause of cardiomyopathy familial hypertrophic type 18 (CMH18) [MIM:613874]. CMH18 is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
• Sequence similaritiesBelongs to the phospholamban family.
• Post-translational
  modificationsPhosphorylated in response to beta-adrenergic stimulation.
• Cellular localizationMitochondrion membrane. Sarcoplasmic reticulum.

Target information above from: UniProt accession P26678 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 5350 Human
  • Entrez Gene: 18821 Mouse
  • Omim: 172405 Human
  • SwissProt: P26678 Human
  • SwissProt: P61014 Mouse
  • Unigene: 170839 Human
  • Unigene: 34145 Mouse

• Alternative names
  Cardiac phospholamban antibodyCMD1P antibodyCMH18 antibody

  PLB antibodyPLN antibodyPPLA_HUMAN antibody

  see all

Anti-Phospholamban (phospho S16) antibody [EPR1911] images

• 

  Western blot - Phospholamban (phospho S16) antibody [EPR1911] (ab92697)
  All lanes : Anti-Phospholamban (phospho S16) antibody [EPR1911] (ab92697) at 1/200000 dilution
  
  Lane 1 : Fetal heart lysate (untreated)
  Lane 2 : Fetal heart lysate (treated with LP)
  
  Lysates/proteins at 10 µg per lane.
  
  Secondary
  HRP labelled Goat anti-Rabbit antibody at 1/2000 dilution
  
  Predicted band size : 6 kDa